Related Experiment Video
Updated: Sep 30, 2025
09:16
Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
7.4K
Epigenetic remodeling in heart failure with preserved ejection fraction
Samuele Ambrosini1, Era Gorica1,2, Shafeeq A Mohammed1
1Center for Molecular Cardiology, University of Zurich, Zurich, Switzerland.
Current Opinion in Cardiology
|March 11, 2022
Summary
Epigenetic modifications play a crucial role in heart failure with preserved ejection fraction (HFpEF). Targeting these epigenetic changes offers new therapeutic strategies for managing HFpEF.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Genetics
Background:
- Heart failure with preserved ejection fraction (HFpEF) is associated with poor prognosis.
- Novel molecular targets and therapeutic strategies for HFpEF are urgently needed.
- Epigenetic signals are increasingly recognized for their role in regulating transcriptional programs in HFpEF.
Purpose of the Study:
- To critically review the role of epigenetic processing in HFpEF.
- To explore the therapeutic modulation of epigenetic mechanisms in HFpEF.
- To highlight the potential of epigenetic insights for future HFpEF management.
Main Methods:
- Review of emerging evidence on epigenetic involvement in HFpEF.
- Analysis of chromatin dynamics and the development of epigenetic drugs.
- Discussion of computational epigenetics and deep machine learning applications.
Main Results:
- Epigenetic signatures acquired during life can disrupt molecular pathways in HFpEF.
- Understanding chromatin dynamics enables the development of drugs to modify transcriptional changes.
- Epigenetic information can be used to identify biomarkers and develop predictive models for HFpEF.
Conclusions:
- Epigenetic modifications are integral to HFpEF pathogenesis.
- Personalized epigenetic biomarkers and therapies hold promise for combating HFpEF.
- Investigating the individual epigenetic landscape is key to future HFpEF treatment strategies.
More Related Videos
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.6K
09:37Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
Published on: December 2, 2014
28.1K
Related Concept Videos
01:29Heart Failure II: Pathophysiology
82
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
82
01:17Pathophysiology of Heart Failure
1.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
543
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
543
01:30Heart Failure V: Medical Management
36
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
36
01:27Heart Failure I: Introduction
95
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
95
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
78
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
78